Orin
COONasdaq·Medical - Instruments & Supplies

The Cooper Companies, Inc. COO

Market cap $11.0BP/E 19.1× trailingGross margin 63.6%
$56.20
+0.13 (+0.23%)live 09:30 ET
52-wk $51.01 – $89.83
Watch
Orin's take
0.58conviction · moderate
Refreshed 30 Aug · take v7. A new filing or a print queues the next refresh.

COO remains a hold. FY2025 revenue grew 5.1% to $4.09B and free cash flow improved to $433.7M from $288.1M on reduced capital expenditure, but gross margin compressed from 66.6% to 60.7%, operating income declined to $682.9M from $705.7M, and diluted EPS fell 4.6% to $1.87 — profitability is eroding even as the top line advances.

The stock has broken below both its 50-day ($72.40) and 200-day ($73.43) moving averages to $71.17 with a bearish MACD histogram and RSI of 39.2, and at 60.3x trailing earnings versus a peer median of 9.0x, the valuation premium leaves no room for further operational disappointment.

What could go wrong

  • Margin compression persists. Gross margin already fell from 66.6% to 60.7% in FY2025; continued cost pressure would deepen the EPS decline and undermine the growth-stock narrative.
  • Valuation de-rating. At 60.3x P/E versus a peer median of 9.0x, any earnings miss could trigger multiple compression alongside the ongoing fundamental deterioration.
  • Rising debt burden. Total debt increased to $2.78B from $2.58B year-over-year, and higher interest costs could further pressure net income.
  • Revenue growth deceleration. Top-line growth has slowed from 8.4% in FY2024 to 5.1% in FY2025; further deceleration would compound the margin compression problem.

What would change my mind

Gross margin stabilization. Next quarterly report shows gross margin recovering toward 64%+bullish
Continued margin erosion. Gross margin remains below 60% in upcoming quartersbearish
Revenue re-acceleration. Quarterly revenue growth returns above 8%bullish
Technical support failure. Stock closes below $68 on heavy volumebearish

Where this comes from: FMP FY2025 / derived_metrics · derived_metrics FY2024–FY2025 · FMP FY2025 / derived_metrics · FMP FY2025 vs FY2024. Orin's read on COO; not advice.

Twelve months actual closes to 2026-09-23 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q4 2023

Money flow
FilerPositionOf fund
Vanguard Group$2.2B0.0% of fund
BlackRock$1.6B0.0% of fund
State Street$801.0M0.0% of fund
Capital World Investors$532.7M0.1% of fund
Alliancebernstein L.P$458.2M0.2% of fund
Geode Capital Management$425.1M0.0% of fund

72 filers · quarter ended Q4 2023 · positions, not flows

Insiders, last 24 months: 118 Form 4 filings, net $2.0M. Of the 50 on hand, 5 were open-market purchases and 0 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about COO

its filings · its transcripts · its numbers

Orin answers questions about COO from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days

Where it trades

vs its own 5y · Healthcare
MetricNowOwn medianSector
P/E19.1×37.3×26.4×
EV/EBITDA14.6×20.2×
P/S2.58×4.29×
P/B1.3×2.0×

Its P/E sits 20th percentile of its own last 5 years (−1.07σ from its own mean).

What the price assumes

10.9%

free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $0.4B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.

What Wall Street published

28 firms · 2026-09-23
Consensus target

$66

$59$75 · +17% against today's price

How they rate it
  • 14 buy or overweight
  • 13 hold
  • 1 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 9.1× of 2 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
COOThe Cooper Companies, Inc.$11B19.1×14.6×63.6%13.5%7%
SOLVSolventum Corporation$15B10.8×7.8×54.7%17.3%29%
UHSUniversal Health Services, Inc.$11B7.4×5.7×90.7%8.4%21%

The median is of the 2 peers listed above and nothing else — check it against the column. This company trades 111.4% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 7.3×FY25 37.2×

What its sector has traded at

Healthcare
FY14 6.5×FY26 28.6×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Discounted cash flow

not recomputed since
ModelFair valueAgainstComputed
Standard DCF$58$68.18 · −15%2026-06-10
Levered DCF$54$68.18 · −21%2026-06-10

The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.

Every estimate on one scale

price $56.20
52-week range$51 – $90
Analyst targets$59 – $75
Standard DCF$58 as of 2026-06-10, when it was $68.18
Levered DCF$54 as of 2026-06-10, when it was $68.18
At own 5y-median P/E (37×)$109
At 5y P/E range (7–53×)$21 – $156
At sector P/E (26×)$77

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.